A. Aguilar

发表

Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2012, Journal of medicinal chemistry.

SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.

Shanghai Yu, Liu Liu, Wei Sun, 2014, Cancer research.

Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression.

Shaomeng Wang, S. Gross, J. Stuckey, 2021, Journal of medicinal chemistry.

Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction.

Liu Liu, Shaomeng Wang, James Delproposto, 2019, Journal of medicinal chemistry.

Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction.

Liu Liu, Shaomeng Wang, J. Stuckey, 2018, Angewandte Chemie.

Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2018, Journal of medicinal chemistry.

Discovery of MD-224 as a First-in-Class, Highly Potent and Efficacious PROTAC MDM2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Liu Liu, Chao-yie Yang, D. McEachern, 2019 .

Alterations in hepatic peroxidation mechanisms in thioacetamide-induced tumors in rats. Effect of a rhodium(III) complex.

D. Craciunescu, A. Aguilar, C. Cascales, 1991, Carcinogenesis.

Strategies for the drug discovery and development of taxane anticancer therapeutics

Changwei Wang, I. Ojima, A. Aguilar, 2022, Expert opinion on drug discovery.

Chemical synthesis of tetracyclic terpenes and evaluation of antagonistic activity on endothelin-A receptors and voltage-gated calcium channels.

B. Zou, P. Wangemann, Aibin Shi, 2015, Bioorganic & medicinal chemistry.

338 BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity

Liu Liu, Shaomeng Wang, Chao-yie Yang, 2014 .

A potent and highly efficacious Bcl-2/Bcl-xL inhibitor.

Liu Liu, Shaomeng Wang, J. Stuckey, 2013, Journal of medicinal chemistry.

Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development

Liu Liu, Shaomeng Wang, Dajun Yang, 2017, Journal of medicinal chemistry.

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

D. Bernard, Yujun Zhao, Shaomeng Wang, 2014, Journal of medicinal chemistry.

Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.

Liu Liu, Chao-Yie Yang, Liu Liu, 2012, Journal of medicinal chemistry.

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.

Liu Liu, Shaomeng Wang, D. McEachern, 2018, Journal of medicinal chemistry.

BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo

Liu Liu, Shaomeng Wang, D. McEachern, 2014, PloS one.

Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.

Chao-Yie Yang, Shaomeng Wang, D. Bernard, 2017, Cold Spring Harbor perspectives in medicine.

Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics

Shaomeng Wang, D. Bernard, Yujun Zhao, 2012 .

Therapeutic Strategies to Activate p53

Shaomeng Wang, A. Aguilar, 2022, Pharmaceuticals.

The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated anti-tumor immunity

Shaomeng Wang, W. Zou, Ilona Kryczek, 2021, Nature Immunology.

Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong In Vivo Antitumor Activity.

Shaomeng Wang, J. Stuckey, D. McEachern, 2020, Journal of medicinal chemistry.

Simple Structural Modifications Converting a Bona Fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.

Zhaomin Liu, Shaomeng Wang, A. Aguilar, 2019, Journal of medicinal chemistry.

Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles

J. Deschamps, Liu Liu, Shaomeng Wang, 2014, Journal of medicinal chemistry.

Targeting the MDM 2 – p 53 Protein – Protein Interaction for New Cancer Therapy : Progress and Challenges

Shaomeng Wang, D. Bernard, Yujun Zhao, 2017 .

Targeting MDM2 for the development of a new cancer therapy: progress and challenges

A. Aguilar, Shaomeng Wang, J. E. Thomas, 2023, Medicinal Chemistry Research.

544 Preclinical studies of a dual Bcl-2/Bcl-xL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity

Shaomeng Wang, Dajun Yang, D. McEachern, 2014 .

Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.

Liu Liu, Shaomeng Wang, J. Stuckey, 2012, Journal of medicinal chemistry.

Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold.

Liu Liu, Shaomeng Wang, Xueliang Fang, 2012, Journal of medicinal chemistry.

Discovery of CW-3308 as a Potent, Selective, and Orally Efficacious PROTAC Degrader of BRD9.

D. McEachern, Mi Wang, Shaomeng Wang, 2024, Journal of medicinal chemistry.